How Do Dysplastic CMML and Proliferative CMML Differ?

Chronic myelomonocytic leukemia (CMML) can be overwhelming, and two people with the disease may have very different day-to-day experiences. To help predict symptoms and guide care, doctors often classify CMML into two clinical patterns, or “phenotypes,” based on the white blood cell count at a given time ^[1][2].

When the white blood cell (WBC) count is strictly below 13,000 per microliter (13 × 10^9/L), it is called dysplastic CMML (MD-CMML). When the WBC count is 13,000 per microliter or higher, it is called proliferative CMML (MP-CMML) ^[1][2].

It is important to know that this simple cutoff does not completely define your disease, diagnosis, or prognosis. The WBC count can fluctuate due to infections, inflammation, or medications like steroids ^[2][3]. Treatment decisions rely on the whole picture—including symptoms, bone marrow results, genetic changes, and formal risk scores—not just the WBC count ^[4][2].

Dysplastic CMML (MD-CMML)

In dysplastic CMML, the disease behaves similarly to a myelodysplastic syndrome (MDS). “Dysplastic” means the bone marrow produces blood cells that do not mature or function properly (ineffective hematopoiesis) ^[5].

Because the marrow struggles to make healthy, working cells, patients with MD-CMML often face cytopenias (low blood counts) ^[6]. Typical issues include:

• Anemia (low hemoglobin or red cell mass): This reduces the oxygen carried through the body, leading to severe fatigue, weakness, and shortness of breath ^[5][6].
• Thrombocytopenia (low platelets): This can increase the risk of easy bruising or abnormal bleeding ^[7].
• Neutropenia (low neutrophils): A drop in this specific type of white blood cell can leave patients more vulnerable to frequent or severe infections ^[7][4].

Proliferative CMML (MP-CMML)

In proliferative CMML, the disease behaves more like a myeloproliferative neoplasm (MPN). “Proliferative” means the bone marrow is overproducing monocytes and other myeloid white blood cells ^[2][8].

While these patients can still experience anemia or low platelets, the high number of white blood cells often causes a different set of symptoms ^[8][9]:

• Splenomegaly (enlarged spleen): Leukemia cells can gather or attempt to produce blood in the spleen. An enlarged spleen can cause abdominal discomfort or a feeling of being full after eating very little ^[8][9].
• Constitutional Symptoms: These are “whole-body” symptoms driven by the overactive disease, including persistent fevers, drenching night sweats, and unintentional weight loss ^[9][10].
• Blood Markers: MP-CMML often features higher levels of lactate dehydrogenase (LDH, a marker of tissue turnover) and sometimes more circulating immature myeloid cells compared to MD-CMML ^[8].

Overlap and Changes Over Time

CMML exists on a spectrum, and it is common for a patient’s phenotype to overlap or change ^[11].

• Changing Phenotype: A person initially diagnosed with dysplastic CMML can experience a rising white blood cell count and transition into the proliferative type ^[11]. A rising WBC does not automatically mean the disease has transformed into acute leukemia, as a doctor will interpret this trend alongside other results.
• Inflammatory Features: Up to 20% of all CMML patients develop systemic inflammatory or autoimmune conditions, such as arthritis, vasculitis, or rashes ^[10][3].
• Risk of Progression: Both types carry a risk of transforming into acute myeloid leukemia (AML) ^[2]. AML transformation is defined by having 20% or more blasts (immature blood-forming cells) in the blood or bone marrow ^[12][2]. While studies suggest that proliferative CMML may progress to AML more quickly on average, an individual patient’s risk depends heavily on their blast percentage, genetics, and other specific factors ^[13][2].

🚨 When to Contact Your Care Team Immediately

Follow your doctor’s specific instructions, but seek prompt medical advice if you experience:

• A fever (often 100.4°F / 38.0°C or higher, but confirm your threshold with your team).
• Significant, unusual, or uncontrolled bleeding.
• Severe or rapidly worsening shortness of breath or chest pain.
• Rapidly worsening abdominal pain or fullness.

Differences in Treatment

Treatment is highly individualized. Doctors do not choose a treatment simply based on whether the disease is dysplastic or proliferative. Instead, they consider symptoms, transfusion needs, overall health, and formal risk scores like the CPSS-Mol or the Mayo Molecular Model ^[4][2].

• Observation and Supportive Care: For patients with lower-risk disease and minimal symptoms, careful monitoring without immediate treatment is appropriate ^[4]. When symptoms arise, supportive care aims to improve quality of life. For example, anemia may be treated with blood transfusions or erythropoiesis-stimulating agents (ESAs, depending on a patient’s natural erythropoietin levels) ^[5][4]. Frequent transfusions require monitoring for iron overload ^[4][14].
• Cytoreduction: For proliferative CMML, controlling the high white blood cell count and shrinking the spleen are top priorities to improve symptoms. Doctors frequently use hydroxyurea, an oral chemotherapy drug ^[4][2]. Hydroxyurea is not a cure and requires close blood-count monitoring to ensure it does not cause severe drops in healthy cells ^[2][5].
• Hypomethylating Agents (HMAs): Drugs like azacitidine or decitabine can be used in either type of CMML to treat worsening counts or higher-risk disease. These require repeated treatment cycles. In one major trial (DACOTA) for high-risk proliferative CMML, patients receiving decitabine had a higher response rate than those on hydroxyurea, but the overall survival time was similar between the two groups ^[2][15].
• Stem Cell Transplant Evaluation: An allogeneic stem cell transplant (using healthy stem cells from a donor) is the only treatment with the potential to cure CMML ^[16]. However, it carries significant risks of severe complications. An early consultation with a transplant specialist is recommended for medically fit patients with intermediate or high-risk disease—regardless of their WBC phenotype—so they can carefully weigh the expected benefits against the potential risks ^[4][2][17].